Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF “LIMAPROST TABLETS” FOR MARKETING2023.02.20
-
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF INNOVATIVE MEDICINE "TQB2103 (Claudin18.2 ADC)" ACCEPTED BY CDE2023.02.10
-
INSIDE INFORMATION - TERMINATION OF LISTING TUTORIAL2023.02.08
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 20232023.02.02
-
REDEMPTION OF THE BONDS2023.01.19
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING OF CATEGORY I INNOVATIVE DRUG TQB2450 INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF FIRST-LINE TREATMENT OF SMALL CELL LUNG CANCER ACCEPTE2023.01.13
-
VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT WITH BOAN BIOTECH2023.01.10
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 20222023.01.03